How to build a biotech unicorn: Get the star team in place, attract deep-pocket VCs, paint a big picture and raise up to $1B
When Steve Harr sketched out the barebones essentials of his strategic plan for the new cell therapy company Sana Biotechnology a few days ago, he was careful to steer clear of detailing his exact plans for his first big raise for the biotech. But some numbers have been starting to appear — and not surprisingly they paint a picture of a young unicorn still at foal stage.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.